<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04944082</url>
  </required_header>
  <id_info>
    <org_study_id>Remdesivir-Ivermectin</org_study_id>
    <nct_id>NCT04944082</nct_id>
  </id_info>
  <brief_title>Remdesivir- Ivermectin Combination Therapy in Severe Covid-19</brief_title>
  <official_title>Remdesivir Versus Remdesivir- Ivermectin Combination Therapy in Severe and Critically Ill Covid-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent study reported in vitro synergistic interaction between two FDA approved drugs,&#xD;
      remdesivir (RDV) and ivermectin (IVM) resulting in enhanced antiviral activity against&#xD;
      SARS-CoV-2, the causative pathogen of COVID-19. The aim of the current study is comparing the&#xD;
      efficacy and safety of combining remdesivir and ivermectin versus using remdesivir alone in&#xD;
      patients with severe COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1- Improvement in level of oxygenation</measure>
    <time_frame>By arterial blood gas and non-invasive pulse oximeter at date of randomisation, after 1 hour then on daily bases in stable cases till time of patient discharge or death</time_frame>
    <description>Change in partial pressure of Oxygen and oxygen saturation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2- Need for ventilator support</measure>
    <time_frame>From date of randomisation to patient discharge from hospital or death.</time_frame>
    <description>either noninvasive or invasive mechanical ventilation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3- Length of hospital stay</measure>
    <time_frame>From date of randomisation to date of patient discharge from hospital or death.</time_frame>
    <description>duration of admission in days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>4- Development of complication</measure>
    <time_frame>From starting to the end of ivermectin therapy (0 to the end of 4th day)</time_frame>
    <description>allergic reactions, arrhythmia, hepatic toxicity.....</description>
  </primary_outcome>
  <primary_outcome>
    <measure>5- Mortality</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
    <description>mortality rates in both groups</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Remdesivir only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>(Dose 200 mg day one, 100 mg daily days 2-5), duration may extend to 10 days of remdesivir (200 mg day one, 100 mg daily days 2-10)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination remdesivir plus ivermectin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(The same remdesivir dose as mentioned + ivermectin 4 tablet (6mg) once daily before meal for four days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>(The same remdesivir dose as mentioned + ivermectin 4 tablet (6mg) once daily before meal for four days)</description>
    <arm_group_label>Combination remdesivir plus ivermectin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult, hospitalized severe COVID-19 patients; both genders; given informed consent&#xD;
             (COVID-19 infection confirmed by PCR, severe illness is defined as patients with SpO2&#xD;
             ≤94% on room air, including patients on supplemental oxygen).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients under 18 years old, pregnant ladies, advanced renal diseases (cr. Clearance &lt;&#xD;
             30 ml/hr), raised liver enzymes&gt; 3 folds of normal, arrhythmia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.</citation>
    <PMID>32251768</PMID>
  </reference>
  <reference>
    <citation>Pizzorno A, Padey B, Dubois J, Julien T, Traversier A, Dulière V, Brun P, Lina B, Rosa-Calatrava M, Terrier O. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Antiviral Res. 2020 Sep;181:104878. doi: 10.1016/j.antiviral.2020.104878. Epub 2020 Jul 15.</citation>
    <PMID>32679055</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>June 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Maiada K. Hashem</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

